Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06487546

Repletion of Ergothioneine in Patients With Kidney Failure

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

ESRD Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Failure, Chronic Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Veterans Affairs Palo Alto

Palo Alto, California, 94304, United States

Location status: Recruiting

Location contact

Tammy Sirich

CONTACT

[email protected]

650-493-5000

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • kidney failure receiving hemodialysis or peritoneal dialysis

Exclusion criteria

  • blood transfusion within 90 days
  • taking supplements which contain ergothioneine

Treatment and study plan

Ergothioneine

Dietary Supplement

Participants will receive ergothioneine capsule daily for 12 weeks.

Placebo

Other

Participants will receive placebo capsule daily for 12 weeks.

Primary outcomes

  1. erythrocyte levels of ergothioneine

    Time frame: weeks 1, 2, 4, 8, and 12 (while taking ergothioneine or placebo); and weeks 16 and 20 (after stopping ergothioneine or placebo)

    ergothioneine levels will be measured in whole blood

Secondary outcomes

  1. plasma levels of ergothioneine

    Time frame: weeks 1, 2, 4, 8, and 12 (while taking ergothioneine or placebo); and weeks 16 and 20 (after stopping ergothioneine or placebo)

    ergothioneine levels will be measured in plasma

Study contacts

Contact information is provided by the study sponsor or research team.

Tammy Sirich, MD

CONTACT

[email protected]

650-493-5000

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start
2025
Primary completion
2029
Study completion
2030
First posted
Jul 5, 2024
Registry last updated
Apr 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.